Should I buy or sell Aclaris Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ACRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRS, but not buy additional shares or sell existing shares. View ACRS analyst ratings or view top-rated stocks .

What is Aclaris Therapeutics' stock price target for 2024?

7 brokerages have issued 1 year price targets for Aclaris Therapeutics' shares. Their ACRS share price targets range from $9.00 to $38.00. On average, they anticipate the company's share price to reach $22.25 in the next twelve months. This suggests a possible upside of 1,694.4% from the stock's current price. View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts .

How have ACRS shares performed in 2024?

Aclaris Therapeutics' stock was trading at $1.05 at the start of the year. Since then, ACRS shares have increased by 18.1% and is now trading at $1.24. View the best growth stocks for 2024 here .

When is Aclaris Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024. View our ACRS earnings forecast .

How were Aclaris Therapeutics' earnings last quarter?

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. The biotechnology company earned $17.57 million during the quarter, compared to analysts' expectations of $3.96 million. Aclaris Therapeutics had a negative net margin of 283.15% and a negative trailing twelve-month return on equity of 64.56%.

What ETF holds Aclaris Therapeutics' stock?

iShares U.S. Pharmaceuticals ETF holds 74,618 shares of ACRS stock, representing 0.16% of its portfolio.

What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?

1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com . Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Aclaris Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD) , Inovio Pharmaceuticals (INO) , Rigel Pharmaceuticals (RIGL) , Sorrento Therapeutics (SRNE) , Trevena (TRVN) , AVEO Pharmaceuticals (AVEO) , Corbus Pharmaceuticals (CRBP) , OPKO Health (OPK) , Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX) .

How do I buy shares of Aclaris Therapeutics?

Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ACRS

Aclaris Therapeutics (ACRS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ACRS Stock Alerts

$1.24

+0.01 (+0.81%)

(As of 04/19/2024 ET)

Compare

Today's Range: $1.21
▼
$1.25
50-Day Range: $1.15
▼
$1.44
52-Week Range: $0.59
▼
$11.12

Volume: 579,779 shs
Average Volume: 1.53 million shs
Market Capitalization: $87.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $22.25

Get Aclaris Therapeutics alerts:

Aclaris Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Hold
2.14 Rating Score
Upside/Downside: 1,694.4% Upside
$22.25 Price Target
Short Interest: Healthy
6.89% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.98) to ($0.87) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.41 out of 5 stars

Medical Sector

714th out of 911 stocks

Pharmaceutical Preparations Industry

318th out of 413 stocks

3.1

Analyst's Opinion

Consensus Rating
Aclaris Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 1 buy rating, 6 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aclaris Therapeutics has only been the subject of 1 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
6.89% of the outstanding shares of Aclaris Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Aclaris Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aclaris Therapeutics has recently decreased by 4.49%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Aclaris Therapeutics does not currently pay a dividend.
Dividend Growth
Aclaris Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACRS.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Aclaris Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aclaris Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.50% of the stock of Aclaris Therapeutics is held by insiders.
Percentage Held by Institutions
98.34% of the stock of Aclaris Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aclaris Therapeutics are expected to grow in the coming year, from ($0.98) to ($0.87) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aclaris Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aclaris Therapeutics is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aclaris Therapeutics has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About Aclaris Therapeutics Stock (NASDAQ:ACRS)

Aclaris Therapeutics, Inc. a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment provides laboratory services. It develops Zunsemetinib (ATI-450), an MK2 inhibitor which is under Phase 1b/2 trials for the treatment of metastatic breast and pancreatic cancer; ATI-1777, a soft JAK 1/3 inhibitor, completed Phase 2b trails for the treatment of moderate to severe atopic dermatitis and other dermatologic conditions; and ATI-2138, an oral covalent inhibitor of ITK and JAK3 inhibitor under Phase 1 trials as a treatment for T cell-mediated autoimmune diseases. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

ACRS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACRS Stock News Headlines

April 11, 2024 | finance.yahoo.com

Favourable Signals For Aclaris Therapeutics: Numerous Insiders Acquired Stock

March 16, 2024 | finance.yahoo.com

ACRS Apr 2024 1.000 call

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 4, 2024 | markets.businessinsider.com

Aclaris Therapeutics: Cautious Hold Rating Amid Financial Stability and Pipeline Potential

March 1, 2024 | markets.businessinsider.com

Aclaris Therapeutics: Hold Rating Amidst Strategic Review and Clinical Setbacks

February 29, 2024 | finance.yahoo.com

Analysts Have Just Cut Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Revenue Estimates By 51%

February 27, 2024 | msn.com

Aclaris Therapeutics GAAP EPS of -$0.02 beats by $0.31, revenue of $17.6M beats by $12.55M

February 27, 2024 | globenewswire.com

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

April 20, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

February 20, 2024 | finance.yahoo.com

Pacira (PCRX) Earnings Expected to Grow: What to Know Ahead of Q4 Release

February 15, 2024 | finance.yahoo.com

Will Aclaris Therapeutics (ACRS) Report Negative Q4 Earnings? What You Should Know

February 6, 2024 | msn.com

Aclaris Therapeutics Executive Team Undergoes Major Changes

January 22, 2024 | msn.com

HW Wainwright cuts Aclaris to neutral, cites underwhelming study data

January 16, 2024 | msn.com

Why Is Dermatology Focused Aclaris Therapeutics Stock Trading Higher Today?

January 16, 2024 | bizjournals.com

Aclaris moves on from CEO and begins strategic review following recent setbacks

January 11, 2024 | msn.com

BTIG Downgrades Aclaris Therapeutics (ACRS)

January 11, 2024 | markets.businessinsider.com

The Analyst Landscape: 4 Takes On Aclaris Therapeutics

January 11, 2024 | realmoney.thestreet.com

Jefferies gets more bearish on Aclaris Therapeutics, downgrades shares

January 10, 2024 | msn.com

Aclaris downgraded at Jefferies despite mid-stage win for eczema therapy

January 10, 2024 | markets.businessinsider.com

Analyst Highlights Aclaris Therapeutics' Encouraging Efficacy For Eczema Candidate, But Cautions On Data Variations

January 10, 2024 | msn.com

Aclaris Therapeutics Shares Fall On Mixed Results From Mid-Stage Eczema Trial

January 10, 2024 | marketwatch.com

Aclaris Therapeutics Shares Down 12% Following Top-Line Results for Atopic Dermatitis Treatment

January 10, 2024 | markets.businessinsider.com

Aclaris Therapeutics Reports Positive Top-line Results From Phase 2b ATI-1777-AD-202 Study

January 10, 2024 | finance.yahoo.com

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

January 4, 2024 | msn.com

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

January 2, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Aclaris Therapeutics (ACRS) and Ocular Therapeutix (OCUL)

December 30, 2023 | markets.businessinsider.com

Buy Rating Justified by Aclaris Therapeutics’ Strategic Focus and Robust Financial Management

See More Headlines

Receive ACRS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aclaris Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/13/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ACRS
CUSIP: N/A
CIK: 1557746
Web: www.aclaristx.com
Phone: (484) 324-7933
Fax: 484-320-2344
Employees: 86
Year Founded: 2012

Price Target and Rating

Average Stock Price Target: $22.25
High Stock Price Target: $38.00
Low Stock Price Target: $9.00
Potential Upside/Downside: +1,694.4%
Consensus Rating: Hold
Rating Score (0-4): 2.14
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-88,480,000.00
Net Margins: -283.15%
Pretax Margin: -284.32%
Return on Equity: -64.56%
Return on Assets: -49.10%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.16
Quick Ratio: 4.16

Sales & Book Value

Annual Sales: $31.25 million
Price / Sales: 2.81
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.22 per share
Price / Book: 0.56

Miscellaneous

Outstanding Shares: 70,930,000
Free Float: 67,024,000
Market Cap: $87.95 million
Optionable: Optionable
Beta: 0.22

Social Links

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Dr. Neal S. Walker D.O. (Age 54)
M.D., Co-Founder, President, Chairman & Interim CEO
Comp: $955.69k
Dr. Joseph Monahan Ph.D. (Age 67)
Chief Scientific Officer
Comp: $600.02k
Mr. Kevin Balthaser (Age 36)
Chief Financial Officer
Mr. Matthew Rothman J.D.
General Counsel & Corporate Secretary
Dr. Jon Jacobsen Ph.D.
Senior Vice President of Chemistry
Mr. James Loerop (Age 59)
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACRS Stock Analysis - Frequently Asked Questions

Should I buy or sell Aclaris Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aclaris Therapeutics in the last year. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ACRS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACRS, but not buy additional shares or sell existing shares.
View ACRS analyst ratings or view top-rated stocks.
What is Aclaris Therapeutics' stock price target for 2024?: 7 brokerages have issued 1 year price targets for Aclaris Therapeutics' shares. Their ACRS share price targets range from $9.00 to $38.00. On average, they anticipate the company's share price to reach $22.25 in the next twelve months. This suggests a possible upside of 1,694.4% from the stock's current price.
View analysts price targets for ACRS or view top-rated stocks among Wall Street analysts.
How have ACRS shares performed in 2024?: Aclaris Therapeutics' stock was trading at $1.05 at the start of the year. Since then, ACRS shares have increased by 18.1% and is now trading at $1.24.
View the best growth stocks for 2024 here.
When is Aclaris Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our ACRS earnings forecast.
How were Aclaris Therapeutics' earnings last quarter?: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) issued its quarterly earnings results on Tuesday, February, 27th. The biotechnology company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.07. The biotechnology company earned $17.57 million during the quarter, compared to analysts' expectations of $3.96 million. Aclaris Therapeutics had a negative net margin of 283.15% and a negative trailing twelve-month return on equity of 64.56%.

What ETF holds Aclaris Therapeutics' stock?: iShares U.S. Pharmaceuticals ETF holds 74,618 shares of ACRS stock, representing 0.16% of its portfolio.
What is Neal Walker's approval rating as Aclaris Therapeutics' CEO?: 1 employees have rated Aclaris Therapeutics Chief Executive Officer Neal Walker on Glassdoor.com. Neal Walker has an approval rating of 100% among the company's employees. This puts Neal Walker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Aclaris Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aclaris Therapeutics investors own include TherapeuticsMD (TXMD), Inovio Pharmaceuticals (INO), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Trevena (TRVN), AVEO Pharmaceuticals (AVEO), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Abeona Therapeutics (ABEO) and Aldeyra Therapeutics (ALDX).
How do I buy shares of Aclaris Therapeutics?: Shares of ACRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACRS) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial